Endogenous Iron(II) Self-Enriched Fenton Nanocatalyst via FTH1 Activity Inhibition and Iron(III) Reduction for Amplified Cancer Ferroptosis Therapy
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.4c01292 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Ying Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province (The High Efficacy Application of Natural Medicin…. Hauptthemen laut MEDLINE: Ferroptosis, Iron, Neoplasms, Nanoparticles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guizhou Province, Guizhou Provincial Scientific and Technologic Innovation Base.
Abstract (Originalsprache)
Due to the increased expression of iron storage proteins in cancer cells, utilizing the endogenous iron-catalyzed Fenton reaction for cancer ferroptosis therapy has recently emerged as a prominent research focus. However, endogenous iron primarily exists within ferroxidase FTH1 in the Fe (III)-bound state, hindering the effective catalysis of the Fenton reaction. Herein, an endogenous iron(II) self-enriched Fenton nanocatalyst (BAI@cLANCs) is fabricated by encapsulating the FTH1 inhibitor baicalin (BAI) in cross-linked lipoic acid nanocarriers (cLANCs) to amplify endogenous ferroptosis. Once internalized, BAI@cLANCs are disrupted by glutathione (GSH) in tumor cells to release BAI, which inhibits FTH1 activity and hinders Fe2+ oxidation. Meanwhile, cLANCs degrade into dihydrolipoic acid (DHLA), which reduces Fe3+ to Fe2+, synergically enriching endogenous Fe2+. Simultaneously, both BAI and DHLA stimulate H2O2 production and facilitate the Fenton reaction to produce abundant ·OH, thereby triggering lipid peroxidation and inducing tumor ferroptosis. Moreover, the reduction of Fe3+ to Fe2+ depletes GSH, facilitating ·OH production and inactivating glutathione peroxidase-4, ultimately amplifying tumor ferroptosis. Overall, this work highlights the potential of an endogenous iron(II) self-enriched Fenton nanocatalyst for cancer ferroptosis therapy, providing a paradigm for amplifying endogenous ferroptosis by inhibiting FTH1 activity and reducing iron(III) to enrich endogenous iron(II).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province (The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province and The High Educa…
- The State Key Laboratory of Functions and Applications of Medicinal Plants (The Key Laboratory of Endemic and Ethnic Diseases of Ministry of Education) & State Key Laboratory of Discovery and Utilization of Functional C…
- State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing, Jiangsu 210009, China.
- Zunyi Medical and Pharmaceutical College, Zunyi, Guizhou 563006, China.
ORCID-Profile: Ying Chen, Yongchao Yao, Linjing Wu
Förderung
- National Natural Science Foundation of China
- Guizhou Province
- Guizhou Provincial Scientific and Technologic Innovation Base
- High-level Innovation Talents of Guizhou
Zitieren
APA
Chen, Y., Ma, Q., Zhang, J., Li, J., Wang, Y., Yao, Y., Ding, Y., Dai, X., Luo, X., Wu, L., Tao, L., & Shen, X. (2025). Endogenous Iron(II) Self-Enriched Fenton Nanocatalyst via FTH1 Activity Inhibition and Iron(III) Reduction for Amplified Cancer Ferroptosis Therapy. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c01292
Vancouver
Chen Y, Ma Q, Zhang J, Li J, Wang Y, Yao Y, et al. Endogenous Iron(II) Self-Enriched Fenton Nanocatalyst via FTH1 Activity Inhibition and Iron(III) Reduction for Amplified Cancer Ferroptosis Therapy. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c01292
BibTeX
@article{Chen2025,
author = {Chen, Ying and Ma, Qin and Zhang, Jun and Li, Jianhang and Wang, Yu'e and Yao, Yongchao and Ding, Yang and Dai, Xin and Luo, Xinghong and Wu, Linjing and Tao, Ling and Shen, Xiangchun},
title = {Endogenous Iron(II) Self-Enriched Fenton Nanocatalyst via FTH1 Activity Inhibition and Iron(III) Reduction for Amplified Cancer Ferroptosis Therapy},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.4c01292}
}
EUVIMED